Pages that link to "Q40153697"
Jump to navigation
Jump to search
The following pages link to Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection (Q40153697):
Displaying 50 items.
- The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis (Q21132685) (← links)
- Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future (Q24600011) (← links)
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer (Q24607403) (← links)
- The clinical development process for a novel preventive vaccine: An overview (Q26770871) (← links)
- Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus (Q26799574) (← links)
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. (Q26828840) (← links)
- Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial (Q28750269) (← links)
- Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study (Q30980654) (← links)
- HPV infection and cervical disease: a review (Q33159907) (← links)
- Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial (Q33396689) (← links)
- Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia (Q33620823) (← links)
- Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women (Q33622107) (← links)
- Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial (Q33626255) (← links)
- Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits. (Q33863923) (← links)
- Is administration of the HPV vaccine during pregnancy feasible in the future? (Q33920755) (← links)
- Current understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA). (Q34074596) (← links)
- Asian society of gynecologic oncology workshop 2010 (Q34167035) (← links)
- Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data (Q34210255) (← links)
- Risk of human papillomavirus-related cancers among kidney transplant recipients and patients receiving chronic dialysis--an observational cohort study (Q34802753) (← links)
- Sexual behavior and factors associated with young age at first intercourse and HPV vaccine uptake among young women in Germany: implications for HPV vaccination policies (Q34897737) (← links)
- End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. (Q35108338) (← links)
- Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway (Q35127307) (← links)
- A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers. (Q35154570) (← links)
- Construction and characterisation of a recombinant fowlpox virus that expresses the human papilloma virus L1 protein. (Q35595612) (← links)
- Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies. (Q35677956) (← links)
- Human papillomavirus vaccine intent and uptake among female college students (Q35838751) (← links)
- Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial (Q35886910) (← links)
- Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years (Q35918834) (← links)
- Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients (Q36093327) (← links)
- The Effect of Cryotherapy on Human Papillomavirus Clearance Among HIV-Positive Women in Lusaka, Zambia (Q36094880) (← links)
- A review of clinical trials of human papillomavirus prophylactic vaccines (Q36286303) (← links)
- Asia Pacific: cervical cancer screening and human papillomavirus vaccination policy and delivery (Q36984766) (← links)
- Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention (Q37066141) (← links)
- An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results (Q37073522) (← links)
- Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years. (Q37118381) (← links)
- Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials (Q37425284) (← links)
- Virus-like particle vaccines and adjuvants: the HPV paradigm (Q37608311) (← links)
- Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. (Q37702739) (← links)
- Cost–effectiveness of catch-up programs in human papillomavirus vaccination (Q37798010) (← links)
- Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (Q37802641) (← links)
- Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women (Q37818140) (← links)
- Clinical Perspectives on the Role of the Human Papillomavirus Vaccine in the Prevention of Cancer (Q37848402) (← links)
- Spotlight on Quadrivalent Human Papillomavirus(Types 6, 11, 16, 18) Recombinant Vaccine(Gardasil®) in the Prevention of PremalignantGenital Lesions, Genital Cancer, and Genital Warts in Women† (Q37937705) (← links)
- Q & A: Patient to Physician FAQs: Answers to Common Patient Questions About Vaccinations (Q37957510) (← links)
- Prophylactic human papillomavirus vaccines: past, present and future (Q37967012) (← links)
- Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development (Q38059059) (← links)
- Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts (Q38229304) (← links)
- The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials (Q38863385) (← links)
- A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers (Q39285032) (← links)
- Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection (Q39760748) (← links)